Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, central nervous system, anti-infectives, epilepsy, allergy and vitamins, and minerals and supplements, as well as pain care and nutritional health under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. It also exports its products to approximately 35 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.

Revenue projections:

Revenue projections for SANOFI
Revenue projections for SANOFI

SANOFI is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 1.849000
forwardPE 27.931936
debtToEquity 2.672000
earningsGrowth -0.326000
revenueGrowth -0.123000
grossMargins 0.508400
operatingMargins 0.211170
trailingEps 157.520000
forwardEps 203.770000

Sanofi India Limited's current ratio, being 1.849, means the company is well-positioned to meet its short-term debt obligations. This reflects Sanofi India Limited's strong liquidity, as its cash reserves and current assets provide more than enough coverage for its immediate liabilities.
SANOFI's Forward PE is in an attractive range, meaning its stock price aligns well with earnings and isn't inflated. This creates room for growth, making it a solid investment opportunity for those looking to benefit from potential price appreciation.
SANOFI's low earnings and revenue growth highlight a potential decline in profitability. This suggests that the company's financial health may be weakening, and profits could shrink as a result.
SANOFI's positive gross and operating margins suggest strong profitability. These margins reflect effective cost management and revenue generation, indicating that the company is efficiently managing its operations and maintaining financial health.
Sanofi India Limited's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in Sanofi India Limited's earnings potential, suggesting stronger financial performance compared to the previous year.

Price projections:

Price projections for SANOFI
Price projections for SANOFI

SANOFI's price projections have gradually declined, indicating growing uncertainty about the company's ability to meet previous targets. The downward trend reflects a more conservative view of SANOFI's future.

Recommendation changes over time:

Recommendations trend for SANOFI
Recommendations trend for SANOFI


Analysts are favoring Sanofi India Limited with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider Sanofi India Limited as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.